Employees at Achilles Therapeutics are bracing themselves ... tumour-targeting platform called PELEUS that is used to identify clonal neoantigens in a patient. "We are actively exploring new ...

London-based Achilles has a bioinformatics platform called PELEUS that can identify clonal neoantigens in a patient, and an automated production platform – known as VELOS – to make the therapy.

Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop ...